MicroPort® Joins Singapore LIVE 2023

Singapore, 20 January 2023 – Singapore LIVE, the most important Singapore Interventional Cardiology event of the year, has been organized by the National Heart Centre of Singapore (NHCS) for over 30 years. MicroPort® recently participated in the Singapore LIVE 2023 conference presenting on a total solution for cardiovascular intervention, and held a satellite session on the topic of “How to optimize percutaneous coronary intervention (PCI) in complex lesions”. This attracted extensive attention from experts and doctors.

Prof Yeo Khung Keong from NHCS was invited to join as the moderator for the symposium, and shared the 5-year outcomes of TARGET All Comers Randomized Trial of Firehawk® Rapamycin Target Eluting Coronary Stent System (Firehawk®) during the session. Dr. Anek Kanoksilp, Director of the Central Chest Institute of Thailand, also attended and presented a LM Bifurcation case treated by Firehawk Liberty™ Rapamycin Target Eluting Coronary Stent System (Firehawk Liberty™), emphasizing the proficiencies of Firehawk Liberty™, such as overexpansion capability and cell size.

With the success of Singapore LIVE 2023, MicroPort® was able to explore its presence in the Singaporean market with global experts, presenting the results of clinical studies and showcasing successful applications in complex lesions. In the future, MicroPort® will continue to pursue innovation with the most advanced products for a total Interventional Cardiology solution.

About MicroPort®

Founded in Shanghai in 1998 on the belief that every person has the right to high quality medical treatments, MicroPort Scientific Corporation (“MicroPort®”, stock code: 00853.HK) is today a global medical devices company with over 12,000 employees worldwide. We provide solutions across twelve therapeutic areas, including orthopedics, cardiac rhythm management, electrophysiology and endovascular. At MicroPort®, we are breaking barriers and accelerating access to life-changing solutions with the purpose of prolonging and reshaping the lives of patients everywhere. Our therapeutic solutions are available in more than 100 countries and over 20,000 hospitals around the world, and today, a patient benefits from a MicroPort® solution every six seconds.

More information is available at microport.com.